logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Return

IOP Matters

delete2025-08-22
delete0
PRE
AI
S
Sasan Moghimi
C
Christopher Girkin
R
Robert N. Weinreb *
DOI：10.1016/j.ogla.2025.07.008delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
To date, evidence from multiple randomized controlled trials has shown that effective intraocular pressure (IOP) lowering therapy significantly reduces the risk of glaucomatous progression across all stages of the disease. Changes in IOP have a substantial impact on the load-bearing connective tissues of the optic nerve head (ONH), as well as the overlying neurovascular tissues of the ONH and retina. An initial treatment goal of reducing IOP by 25% to 35%—and possibly more in advanced cases—can help prevent progression. Additionally, maintaining stable IOP by minimizing both diurnal and long-term fluctuations may further enhance disease control and reduce the risk of worsening.
Keywords:
intraocular pressure
glaucoma progression
optic nerve head
neurovascular tissues
IOP lowering therapy

Journal

Ophthalmology Glaucoma cover
Ophthalmology Glaucoma
IF:
3.2
Papers:
220
Citations:
1.1K

Organization

No organization information available